Advertisement

Rheumaderm pp 215-220 | Cite as

Incidence of Antiperinuclear Factor in Patients with Psoriatic Arthritis

  • P. G. Calzavara-Pinton
  • F. Franceschini
  • C. Manera
  • C. Zane
  • E. Prati
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

Antiperinuclear factor (APF) is considered a disease marker of rheumatoid arthritis (RA) and its diagnostic value is obvious in patients who are seronegative for rheumatoid factor (RF) activity.

We have evaluated APF positivites in 76 patients with psoriatic arthritis, 38 uncomplicated psoriatic patients, 119 patients with non-inflammatory rheumatic diseases (NIRD), 36 RF- and 123 RF + RA patients and 204 healthy controls. APFs were investigated with an indirect immunofluorescence (IIF) test using epithelial cells from human buccal mucosa as a substrate.

6/ 76 (7.9%) PA patients were APF+. The incidence was greater than in healthy controls (2/ 204; p<0.01) and similar to the incidences in patients with uncomplicated psoriasis (1/ 38; p=NS) and patients with non-inflammatory rheumatic disease NIRD (5/ 119; p=NS). However, the incidence was much lower than in RF- (19/ 36; p< 0.001) as well as RF+ (111/ 123; p< 0.001) RA patients. Finally, we emphasise that 3 out of 6 APF positivities shown by PA patients were found in our 3 patients with pustolotic arthroosteitis, a new specific entity in the spectrum of PA.

Keywords

Rheumatoid Arthritis Rheumatoid Arthritis Patient Rheumatoid Factor Psoriatic Arthritis Psoriatic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Manera C, Franceschini F, Cretti L, Braga S, Cattaneo R. Clinical heterogeneity of Rheumatoid Arthritis and the antiperinuclear factor. J Rheumatol, 21: 2021–5. 1994.PubMedGoogle Scholar
  2. 2.
    Janssens X, Veys EM, Verbruggen G, Deleclerq L. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 15: 1346–50. 1988.PubMedGoogle Scholar
  3. 3.
    Youinou P, Massè R, Peu-Duvallon P, Le Roux P, Grulier A, Miossec P, Dorval JC, Lizan G, Ferec C, Le Goff P. Anticorps anti-perinucleaires dans le psoriasis. Ann Dermatol Venereol (Paris) 109: 359–64. 1982.Google Scholar
  4. 4.
    Johnson GD, Carvalho A, Holbrow EJ, Goddard DH, Russel G. Antiperinuclear factor and keratin antibodies in rheumatoid arthritis. Ann Rheum Dis 40: 263–6. 1981.PubMedCrossRefGoogle Scholar
  5. 5.
    Youinou P, Le Goff P, Dumay A, Lelong A, Fauquert P; Jouquan J. The antiperinuclear factor. I. Clinical and serological associations. Clin Exp Rheumatol 8: 259–64. 1990.PubMedGoogle Scholar
  6. 6.
    Berthelot JM, Castagne A, Maugars Y, Audrain M, Barrier J, Prost A. High diagnostic value of antiperinuclear factor-IgG: prospective analysis of 1004 sera diluted 1: 100 and more. Br J Rheumatol 34: 87–8. 1995.PubMedCrossRefGoogle Scholar
  7. 7.
    Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55–78. 1973.PubMedCrossRefGoogle Scholar
  8. 8.
    Ruzicka T. Psoriatic Arthritis. New types, new treatments. Arche dermatol 132: 215–219. 1996.Google Scholar
  9. 9.
    Hradil E, Gentz CF, Matilainen T, Möller H, Sauzen L, Uden a. skeletal involvement in pustolosis palmoplantaris with special reference to sternoclavicular joint. Acta Derm Venereol 68: 65–73. 1988.PubMedGoogle Scholar
  10. 10.
    Jurik AG, Ternowitz T. Frequency of skeletal disease: arthro-osteitis with pustolosis palmo-plantaris. J Am Acad Dermatol 18: 666–671. 1988.PubMedCrossRefGoogle Scholar
  11. 11.
    Ropes MW, Bennett GA, Cobb S et al. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9: 175–6. 1958.PubMedGoogle Scholar
  12. 12.
    Sondag-Tschroots IRJM, Aaij G, Smith JW, Feltkamp TEW. The diagnostic significance of the perinuclear factor for rheumatoid arthritis. Ann Rheum Dis 38: 248–51. 1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Westgeest AAA, Boerbooms AMT, van de Putte LBA. The influence of serum dilution on findings of antiperinuclear factor prevalence in rheumatoid arthritis. Arthritis Rheum 33: 759–60. 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Veys EM, De Keyser F, DeVlam K, Verbruggen G. The antiperinuclear factor. Clin Exp Rheumatol 8: 429–31. 1990.PubMedGoogle Scholar
  15. 15.
    Meinardi MM, deRie MA, Bos JD. Oral cyclosporine A is effective in clearing persistent pustolosis palmoplantaris. Acta Derm venereol (Stock) 70: 77–79. 1990.Google Scholar
  16. 16.
    Danno K, Okamoto H, Imamura S, Ofuji S. Assessment of anti-stratum corneum antibody titres in pustolosis plamaris et plantaris. Br J Dermatol 107: 183–187. 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Enfors W, Molin L. Pustolosis palmaris et plantaris. A follow-up study of a ten-year material. Acta derm Venereol (Stockh) 51: 289–294. 1971.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • P. G. Calzavara-Pinton
    • 1
  • F. Franceschini
    • 2
  • C. Manera
    • 2
  • C. Zane
    • 1
  • E. Prati
    • 2
  1. 1.Department of DermatologyUniversity of BresciaBresciaItaly
  2. 2.Spedali Civili and Clinical Immunology UnitUniversity of BresciaBresciaItaly

Personalised recommendations